AZOLE DRUG-RESISTANCE AS A CAUSE OF CLINICAL RELAPSE IN AIDS PATIENTS WITH CRYPTOCOCCAL MENINGITIS

[1] Spitzer E.D., Spitzer S.G., Freundlich L.F., Casadevall A., Persistence of the initial infection in recurrent cryptococcal meningitis, Lancet, 341, pp. 595-596, (1992)

[2] Casadevall A., Spitzer E., Webb D., Rinaldi M., Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole, Antimicrob Agents Chemother, 37, pp. 1383-1386, (1993)

[3] Velez J.D., Allendoefer R., Luther M., Rinaldi M.G., Graybill J.R., Correlation of in vitro susceptibility with in vivo response in a murine model of cryptococcal meningitis, J I D, 168, pp. 508-510, (1993)

[4] Foulds G., Brennan D.R., Wajszczuk C., Et al., Fluconazole penetration into cerebrospinal fluid in humans, J Clin Pharmacol, 28, pp. 363-366, (1988)

[5] Johnson E.M., Richardson M.D., Warnock D.W., In-vitro resistance to imidazole antifungals in Candida albicans, J Antimicrob Chemother, 13, pp. 547-558, (1984)

[6] Warnock D.W., Methods with antifungal drugs, Medical mycology

[7] a practical approach., pp. 235-259, (1989)

[8] Como J.A., Dismukes W.E., Oral azole drugs as systemic antifungal therapy, N Engl J Med, 330, pp. 263-272, (1994)

[9] Coker R.J., Viviani M., Gazzard B.G., Et al., Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS, AIDS, 7, pp. 829-835, (1993)

[10] Berry A.J., Rinaldi M.G., Graybill J.R., Use of high dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS, Antimicrob Agents Chemother, 32, pp. 690-692, (1992)

[1] Spitzer E.D., Spitzer S.G., Freundlich L.F., Casadevall A., Persistence of the initial infection in recurrent cryptococcal meningitis, Lancet, 341, pp. 595-596, (1992)

[2] Casadevall A., Spitzer E., Webb D., Rinaldi M., Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole, Antimicrob Agents Chemother, 37, pp. 1383-1386, (1993)

[3] Velez J.D., Allendoefer R., Luther M., Rinaldi M.G., Graybill J.R., Correlation of in vitro susceptibility with in vivo response in a murine model of cryptococcal meningitis, J I D, 168, pp. 508-510, (1993)

[4] Foulds G., Brennan D.R., Wajszczuk C., Et al., Fluconazole penetration into cerebrospinal fluid in humans, J Clin Pharmacol, 28, pp. 363-366, (1988)

[5] Johnson E.M., Richardson M.D., Warnock D.W., In-vitro resistance to imidazole antifungals in Candida albicans, J Antimicrob Chemother, 13, pp. 547-558, (1984)

[6] Warnock D.W., Methods with antifungal drugs, Medical mycology

[7] a practical approach., pp. 235-259, (1989)

[8] Como J.A., Dismukes W.E., Oral azole drugs as systemic antifungal therapy, N Engl J Med, 330, pp. 263-272, (1994)

[9] Coker R.J., Viviani M., Gazzard B.G., Et al., Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS, AIDS, 7, pp. 829-835, (1993)

[10] Berry A.J., Rinaldi M.G., Graybill J.R., Use of high dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS, Antimicrob Agents Chemother, 32, pp. 690-692, (1992)